ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the disposal of its equity interest in a wholly-owned subsidiary, effectively removing it from the company’s consolidated financial statements. The transaction, subject to certain conditions, involves a purchase price of up to RMB98.19 million and does not require shareholder approval. Investors are advised to exercise caution regarding this discloseable transaction.
For further insights into HK:1541 stock, check out TipRanks’ Stock Analysis page.